Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib.

Lung cancer (Amsterdam, Netherlands) - 1 Aug 2017

Zhu Viola W, Cui J Jean, Fernandez-Rocha Maria, Schrock Alexa B, Ali Siraj M, Ou Sai-Hong Ignatius

Abstract excerpt

Patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) derive significant clinic benefit from treatment with ALK inhibitors. Crizotinib was the first approved tyrosine kinase inhibitor (TKI) for this distinct molecular subset of NSCLC. Disease progression on TKI inevitably arises secondary to diverse resistance mechanisms among which emergence of secondary ALK mutations is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Crizotinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Conformation

Share to Pyrazoles

Share to Pyridines

Share to Receptor Protein-Tyrosine Kinases

Share to Sulfones

Share to Translocation, Genetic

Source

Identifiers

PMID: 28676215
DOI: 10.1016/j.lungcan.2017.05.018

Genes

ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib.PMID 28676215Read ↗

A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.Semantic proximity Read ↗

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.Semantic proximity Read ↗

Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.Semantic proximity Read ↗

Acquired ALK L1152R Mutation Confers Resistance to Ceritinib and Predicts Response to Alectinib.Semantic proximity Read ↗

ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.Semantic proximity Read ↗

Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC.Semantic proximity Read ↗

Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.Semantic proximity Read ↗

A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature ReviewSemantic proximity Read ↗

Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non-small-cell Lung Cancer Exhibiting Resistance to Ceritinib.Semantic proximity Read ↗

Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA.Semantic proximity Read ↗

Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.Semantic proximity Read ↗

ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.